SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Share this page:

Title

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Subject

Description

Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies.

Date Last Updated (Year-Month-Day)

2020-10-13

Citation

Poland, Gregory A., Inna G. Ovsyannikova, and Richard B. Kennedy. 2020. "SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates." The Lancet.

Abstract

Summary

Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.

Accessibility

Free online on Lancet site.